老年慢性肺心病并发Ⅱ型呼衰患者应用BiPAP治疗的疗效及可行性研究(1)
【摘要】 目的：研究老年慢性肺心病并发Ⅱ型呼衰患者应用BiPAP治疗的疗效及可行性。方法：随机选取2013年2月-2015年12月本院收治的老年慢性肺心病并发Ⅱ型呼衰患者142例，依据辅助通气方法将其分为两组，即BiPAP治疗组和常规治疗组，每组71例。对两组RR、HR、血气分析检测指标及CRP水平、临床疗效进行统计分析。结果：BiPAP治疗组RR、HR均低于常规治疗组，SaO2、PaO2水平均高于常规治疗组，PaCO2、CRP水平均低于常规治疗组(P<0.05)，总有效率85.9%(61/71)高于常规治疗组的54.9%(39/71)，差异均有统计学意义(P<0.05)。结论：老年慢性肺心病并发Ⅱ型呼衰患者应用BiPAP治疗的疗效显著，具有较高的可行性。
【关键词】 老年慢性肺心病并发Ⅱ型呼衰； BiPAP； 可行性
Efficacy and Feasibility Study of BiPAP in the Treatment of Elderly Patients with Chronic Pulmonary Heart Disease with Type Ⅱ Respiratory Failure/WU Hai-hua，HUO Min-qin.//Medical Innovation of China，2017，14(11)：097-100
【Abstract】 Objective：To study the efficacy and feasibility of BiPAP in the treatment of elderly patients with chronic pulmonary heart disease with type Ⅱ respiratory failure.Method：142 cases of elderly patients with chronic pulmonary heart disease with type Ⅱ respiratory failure in our hospital from February 2013 to December 2015 were randomly selected，these patients were divided into BiPAP treatment group and conventional therapy group according to the method of assisted ventilation，71 cases in each group.RR，HR，blood gas analysis and detection indicators，CRP levels and clinical effects of two groups were analyzed.Result：RR，HR of BiPAP treatment group were significantly lower than those of conventional therapy group，SaO2，PaO2 were significantly higher than those of conventional therapy group，PaCO2，CRP levels were significantly lower than those of conventional therapy group，the total treatment effective rate was 85.9%(61/71)，which was higher than that of the conventional treatment group’s 54.9%(39/71)，the differences were statistic significant(P<0.05).Conclusion：The efficacy of BiPAP in the treatment of elderly patients with chronic pulmonary heart disease with type Ⅱ respiratory failure is significant，it has high feasibility.
【Key words】 Elderly patients with chronic pulmonary heart disease with type Ⅱ respiratory failure； BiPAP； Feasibility
First-author’s address：New Rong Qi Hospital at Ronggui Street in Shunde District of Foshan City，Foshan 528303，China
doi：10.3969/j.issn.1674-4985.2017.11.027
近年來，在肺心病并发Ⅱ型呼吸衰竭(呼衰)的治疗中，临床对双水平气道无创正压通气
(Bi-level positive airway pressure airway，BiPAP)进行了不断的发展应用。为了对BiPAP治疗的疗效进行深入探讨，本研究统计分析了2013年2月-2015年12月本院收治的老年慢性肺心病并发Ⅱ型呼衰患者142例的临床资料，对老年慢性肺心病并发Ⅱ型呼衰患者应用BiPAP治疗的疗效及可行性研究进行了研究，现报道如下。
1 资料与方法
1.1 一般资料 随机选取2013年2月-2015年12月本院收治的老年慢性肺心病并发Ⅱ型呼衰患者142例，纳入标准：所有患者均依据临床症状和体征及胸片、血气分析等辅助检查确诊为慢性肺心病并发Ⅱ型呼衰，均符合慢性肺心病并发Ⅱ型呼衰诊断标准[1]，均具有正常的神志；排除标准：严重肝肾功能损害、昏迷、有有创通气治疗指征等患者。依据治疗方法将所有患者分为BiPAP治疗组和常规治疗组，每组71例。BiPAP治疗组，年龄63～85岁，病程1～10年，平均(7.2±1.7)年。常规治疗组中，年龄64～85岁，病程2～10年。该研究已经伦理委员会批准，所有研究对象签署知情同意书。两组一般资料比较 两组性别、年龄、病程等一般资料比较，差异均无统计学意义(P>0.05)，具有可比性，见表1。, http://www.100md.com(吴海华 霍敏琴)
【关键词】 老年慢性肺心病并发Ⅱ型呼衰； BiPAP； 可行性
Efficacy and Feasibility Study of BiPAP in the Treatment of Elderly Patients with Chronic Pulmonary Heart Disease with Type Ⅱ Respiratory Failure/WU Hai-hua，HUO Min-qin.//Medical Innovation of China，2017，14(11)：097-100
【Abstract】 Objective：To study the efficacy and feasibility of BiPAP in the treatment of elderly patients with chronic pulmonary heart disease with type Ⅱ respiratory failure.Method：142 cases of elderly patients with chronic pulmonary heart disease with type Ⅱ respiratory failure in our hospital from February 2013 to December 2015 were randomly selected，these patients were divided into BiPAP treatment group and conventional therapy group according to the method of assisted ventilation，71 cases in each group.RR，HR，blood gas analysis and detection indicators，CRP levels and clinical effects of two groups were analyzed.Result：RR，HR of BiPAP treatment group were significantly lower than those of conventional therapy group，SaO2，PaO2 were significantly higher than those of conventional therapy group，PaCO2，CRP levels were significantly lower than those of conventional therapy group，the total treatment effective rate was 85.9%(61/71)，which was higher than that of the conventional treatment group’s 54.9%(39/71)，the differences were statistic significant(P<0.05).Conclusion：The efficacy of BiPAP in the treatment of elderly patients with chronic pulmonary heart disease with type Ⅱ respiratory failure is significant，it has high feasibility.
【Key words】 Elderly patients with chronic pulmonary heart disease with type Ⅱ respiratory failure； BiPAP； Feasibility
First-author’s address：New Rong Qi Hospital at Ronggui Street in Shunde District of Foshan City，Foshan 528303，China
doi：10.3969/j.issn.1674-4985.2017.11.027
近年來，在肺心病并发Ⅱ型呼吸衰竭(呼衰)的治疗中，临床对双水平气道无创正压通气
(Bi-level positive airway pressure airway，BiPAP)进行了不断的发展应用。为了对BiPAP治疗的疗效进行深入探讨，本研究统计分析了2013年2月-2015年12月本院收治的老年慢性肺心病并发Ⅱ型呼衰患者142例的临床资料，对老年慢性肺心病并发Ⅱ型呼衰患者应用BiPAP治疗的疗效及可行性研究进行了研究，现报道如下。
1 资料与方法
1.1 一般资料 随机选取2013年2月-2015年12月本院收治的老年慢性肺心病并发Ⅱ型呼衰患者142例，纳入标准：所有患者均依据临床症状和体征及胸片、血气分析等辅助检查确诊为慢性肺心病并发Ⅱ型呼衰，均符合慢性肺心病并发Ⅱ型呼衰诊断标准[1]，均具有正常的神志；排除标准：严重肝肾功能损害、昏迷、有有创通气治疗指征等患者。依据治疗方法将所有患者分为BiPAP治疗组和常规治疗组，每组71例。BiPAP治疗组，年龄63～85岁，病程1～10年，平均(7.2±1.7)年。常规治疗组中，年龄64～85岁，病程2～10年。该研究已经伦理委员会批准，所有研究对象签署知情同意书。两组一般资料比较 两组性别、年龄、病程等一般资料比较，差异均无统计学意义(P>0.05)，具有可比性，见表1。, http://www.100md.com(吴海华 霍敏琴)